Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis

Han,Bo  Ram; You,Bo  Ra; Park,Woo  Hyun

doi:10.3892/or.2013.2747

Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis

Authors:
- Bo Ram Han
- Bo Ra You
- Woo Hyun Park
View Affiliations

Affiliations: Department of Physiology, Medical School, Research Institute for Endocrine Sciences, Chonbuk National University, Jeonju 561-180, Republic of Korea
Published online on: September 20, 2013 https://doi.org/10.3892/or.2013.2747
Pages: 2999-3005

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Valproic acid (VPA) as a histone deacetylase (HDAC) inhibitor has an anticancer effect. In the present study, we evaluated the effects of VPA on the growth and death of HeLa cervical cancer cells in relation to reactive oxygen species (ROS) and glutathione (GSH). Dose- and time-dependent growth inhibition was observed in HeLa cells with an IC50 of approximately 10 mM at 24 h. DNA flow cytometric analysis indicated that 10 mM VPA induced a G2/M phase arrest of the cell cycle. This agent also induced apoptosis, which was accompanied by the cleavage of PARP, the activation of caspase-3, -8 and -9, and the loss of mitochondrial membrane potential (MMP; ∆Ψm). All the tested caspase inhibitors significantly prevented HeLa apoptotic cell death induced by VPA, whereas TNF-α intensified the apoptotic cell death. With respect to ROS and GSH levels, VPA increased ROS levels and induced GSH depletion. However, N-acetyl cysteine (NAC; an antioxidant) and L-buthionine sulfoximine (BSO; a GSH synthesis inhibitor) did not significantly affect cell death in VPA-treated HeLa cells. In conclusion, VPA inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis and the growth inhibition is independent of ROS and GSH level changes.

View Figures

View References

1	Icardi L, De Bosscher K and Tavernier J: The HAT/HDAC interplay: multilevel control of STAT signaling. Cytokine Growth Factor Rev. 23:283–291. 2012. View Article : Google Scholar : PubMed/NCBI
2	Lu Z, Luo RZ, Peng H, et al: E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. Oncogene. 25:230–239. 2006.PubMed/NCBI
3	Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI
4	Cebrian A, Pharaoah PD, Ahmed S, et al: Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis. 27:1661–1669. 2006. View Article : Google Scholar : PubMed/NCBI
5	Wang L, Zou X, Berger AD, et al: Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res. 1:62–71. 2009.PubMed/NCBI
6	Robey RW, Chakraborty AR, Basseville A, et al: Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm. 8:2021–2031. 2011. View Article : Google Scholar : PubMed/NCBI
7	Pettazzoni P, Pizzimenti S, Toaldo C, et al: Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radic Biol Med. 50:313–322. 2011. View Article : Google Scholar : PubMed/NCBI
8	Frumm SM, Fan ZP, Ross KN, et al: Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol. 20:713–725. 2013. View Article : Google Scholar : PubMed/NCBI
9	Rikiishi H: Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol. 2011:8302602011. View Article : Google Scholar : PubMed/NCBI
10	Lauricella M, Ciraolo A, Carlisi D, et al: SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie. 94:287–299. 2012. View Article : Google Scholar : PubMed/NCBI
11	Carlisi D, Lauricella M, D’Anneo A, et al: The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer. 45:2425–2438. 2009. View Article : Google Scholar
12	Al-Yacoub N, Fecker LF, Mobs M, et al: Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. J Invest Dermatol. 132:2263–2274. 2012. View Article : Google Scholar : PubMed/NCBI
13	Gong K, Xie J, Yi H and Li W: CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 443:735–746. 2012. View Article : Google Scholar : PubMed/NCBI
14	Huang BH, Laban M, Leung CH, et al: Inhibition of histone deacetylase 2 increases apoptosis and p21^Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 12:395–404. 2005. View Article : Google Scholar : PubMed/NCBI
15	Anton M, Horky M, Kuchtickova S, et al: Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears. Ceska Gynekol. 69:3–6. 2004.PubMed/NCBI
16	Shan Z, Feng-Nian R, Jie G and Ting Z: Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo. Asian Pac J Cancer Prev. 13:3977–3982. 2012. View Article : Google Scholar : PubMed/NCBI
17	Machado MC, Bellodi-Privato M, Kubrusly MS, et al: Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J Exp Ther Oncol. 9:85–92. 2011.PubMed/NCBI
18	Han YH, Moon HJ, You BR, et al: Effects of carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone on the growth inhibition in human pulmonary adenocarcinoma Calu-6 cells. Toxicology. 265:101–107. 2009. View Article : Google Scholar
19	You BR and Park WH: Zebularine inhibits the growth of HeLa cervical cancer cells via cell cycle arrest and caspase-dependent apoptosis. Mol Biol Rep. 39:9723–9731. 2012. View Article : Google Scholar : PubMed/NCBI
20	Han YH, Moon HJ, You BR and Park WH: The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 22:215–221. 2009.PubMed/NCBI
21	You BR and Park WH: Proteasome inhibition by MG132 induces growth inhibition and death of human pulmonary fibroblast cells in a caspase-independent manner. Oncol Rep. 25:1705–1712. 2011.PubMed/NCBI
22	Han YH, Kim SH, Kim SZ and Park WH: Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) as an O2(*-) generator induces apoptosis via the depletion of intracellular GSH contents in Calu-6 cells. Lung Cancer. 63:201–209. 2009.
23	Han YH and Park WH: Propyl gallate inhibits the growth of HeLa cells via regulating intracellular GSH level. Food Chem Toxicol. 47:2531–2538. 2009. View Article : Google Scholar : PubMed/NCBI
24	Griffiths EJ: Mitochondria - potential role in cell life and death. Cardiovasc Res. 46:24–27. 2000. View Article : Google Scholar : PubMed/NCBI
25	You BR and Park WH: Suberoyl bishydroxamic acid-induced apoptosis in HeLa cells via ROS-independent, GSH-dependent manner. Mol Biol Rep. 40:3807–3816. 2013. View Article : Google Scholar : PubMed/NCBI
26	Gurvich N, Tsygankova OM, Meinkoth JL and Klein PS: Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 64:1079–1086. 2004. View Article : Google Scholar : PubMed/NCBI
27	Zhao X, Yang W, Shi C, et al: The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells. Tumour Biol. 32:335–346. 2011. View Article : Google Scholar : PubMed/NCBI
28	Das CM, Aguilera D, Vasquez H, et al: Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol. 85:159–170. 2007.PubMed/NCBI
29	Yang J, Liu X, Bhalla K, et al: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
30	Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L and Jaulin C: Histone deacetylase inhibitors and genomic instability. Cancer Lett. 274:169–176. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ungerstedt JS, Sowa Y, Xu WS, et al: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 102:673–678. 2005. View Article : Google Scholar : PubMed/NCBI
32	Han YH, Kim SZ, Kim SH and Park WH: Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by diethyldithiocarbamate or buthionine sulfoximine. Int J Oncol. 33:205–213. 2008.PubMed/NCBI
33	Estrela JM, Ortega A and Obrador E: Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 43:143–181. 2006. View Article : Google Scholar
34	Han YH, Kim SZ, Kim SH and Park WH: Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine. Mol Cells. 26:18–25. 2008.PubMed/NCBI